Emyria LtdASX: EMD

Emyria to Benefit from Final TGA Ruling on CBD Medicines

· Issued by Emyria Ltd

Filed with ASX · · 3 pages · English

● Final decision from Australia’s Therapeutic Goods Administration (TGA) confirms requirement for product-specific safety and efficacy data to support registrationof low-dose CBD products (<150mg/day) as Schedule 3 medicines for all proposed doses and indications ● Emyria Data is one of the largest clinical-trial-grade data sets covering safety and efficacy data on over 3,000 patients for a wide range

Emyria Ltd on 6ix

Earlier from Emyria

Later from Emyria

All Emyria news releases